Conference Coverage

HIV Comorbid Infection and Liver-directed AAV-Based Gene Therapy in Adults With Severe and Moderately Severe Hemophilia B

Long-term Bleeding Protection, Sustained FIX Activity, Reduction of FIX Consumption, and Safety of Hemophilia B Gene Therapy

Development of adeno-associated virus (AAV5) variants capable of reducing the immunogenicity by targeting antigenic residues on the capsid surface

Updates on SPK-8011

Phase 3 HOPE-B Trial of etranacogene dezaparvovec in Severe/Moderately Severe Hemophilia B

Updates from the GENEr8-1 Trial

Residual Burden of Liver Disease After HCV-clearance in Hemophilia: A Word of Caution in the Era of Gene Therapy

Efficacy and Safety of Fidanacogene Elaparvovec in Adults With Moderately Severe or Severe Hemophilia B: Results From the Phase 3 BENEGENE-2 Gene Therapy Trial

Elucidating the Mechanism Behind the AAV-Derived Factor VIII Assay Discrepancy

Relationship Between Transgene-Produced FVIII and Bleeding Rates 2 Years After Gene Transfer With Valoctocogene Roxaparvovec: Results From Gener8-1

Results from B-LIEVE, a Phase 1/2 Dose-Confirmation Study of FLT180a AAV Gene Therapy in Patients With Hemophilia B

Stable Hemostatic Correction and Improved Hemophilia-Related Quality of Life: Final Analysis from the Pivotal Phase 3 HOPE-B Trial of Etranacogene Dezaparvovec

Subcategories

Highlights From the 17th Annual Congress of EAHAD

Highlights From the 65th ASH Annual Meeting and Exposition

Highlights From the ESGCT 30th Annual Congress

Highlights From the 31st Congress of ISTH

Highlights From the 32nd Congress of ISTH

Back To Top
Image

About

Supported through educational grants from BioMarin, CSL Behring, Pfizer Inc., Roche, and Spark Therapeutics

Essential SSL